FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT
obligations may continue. See Instruction 1(b).	Filed pu

## OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  POTTS JOHN T JR  (Last) (First) (Middle)  C/O BIOSANTE PHARMACEUTICALS, INC.  111 BARCLAY BOULEVARD					B] BP	2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [ BPAX ]  3. Date of Earliest Transaction (Month/Day/Year) 03/31/2011									of Reporting Per cable) or (give title		son(s) to Issuer  10% Owner  Other (specify below)		
(Street) LINCOLNSHIRE IL 60069 (City) (State) (Zip)						If Amendment, Date of Original Filed (Month/Day/Year)      tive Securities Acquired, Disposed of, or Benefications								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Tra			2. Trans	action	ear)	2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 5)			5. Amour Securitie	nt of s ally following	Form:	Direct Ir Indirect B str. 4)	'. Nature of ndirect Beneficial Ownership Instr. 4)		
										v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	on(s)		"	11501.4)	
Common Stock													2,0	657		D			
Common Stock														2,9	2,924		I C	Sy Children's 'rust	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date or Exercise (Month/Day/Year) if any		Date,	Code (Instr.				6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reported Transact (Instr. 4)	/e es ally ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ect (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Non- Statutory Stock Option (right to buy)	\$1.98	03/31/2011			A		25,000		03/31/20	12 (	03/30/2021	Common Stock	25,000	\$0	25,0	00	D		

**Explanation of Responses:** 

/s/ Phillip B.

Donenberg, attorney-in-fact

03/31/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).